Meeting
2023 ASCO Annual Meeting
Ovarian cancer and bevacizumab: Real-world use across western countries and effect on survival in high-risk subgroups.
Authors
Kristina Lindemann
Department of gynecological oncology, Radiumhospital, Oslo University Hospital & Faculty of Medicine, University of Oslo, Oslo, Oslo, Norway
Kristina Lindemann , Miguel Abreu , Maria de Lurdes Batarda , Dorry Boll , Anne Weng Ekmann-Gade , Jesper Hansen , Ala Jabri Haug , Claus Høgdall , Jacob Korach , Els Van Nieuwenhuysen , P. B. Ottevanger , Stephan Polterauer , Tine Henrichsen Schnack , Trude Agesen , Sofia Waldemarson , Klaus Kaae Andersen , Christian Marth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5587)
DOI
10.1200/JCO.2023.41.16_suppl.5587
Abstract #
5587
Poster Bd #
282
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer.
First Author: Gordon Taylor Moffat
Poster
2020 ASCO Virtual Scientific Program
Population-adjusted indirect treatment comparison (PAITC) of maintenance PARP inhibitor (PARPi) with or without bevacizumab versus bevacizumab in women with newly diagnosed ovarian cancer (OC).
First Author: Robert Hettle
Poster
2019 ASCO Annual Meeting
Real-world bevacizumab utilization and outcomes in first-line ovarian cancer.
First Author: Matthew J. Monberg
Poster
2018 ASCO Annual Meeting
Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study.
First Author: Robert Allen Burger